We also observed that the ratio of LC3A/B-II/LC3A/B-I was significantly increased by Cur and or SLCP treatment in all three GBM cells lines in comparison to vehicle-treated cells (Figure 1A,D). The gene discussed is MAP1LC3A; the disease is glioblastoma.